Literature DB >> 24025691

Azacitidine induces profound genome-wide hypomethylation in primary myelodysplastic bone marrow cultures but may also reduce histone acetylation.

M Grövdal1, M Karimi1, M Tobiasson1, L Reinius2, M Jansson1, K Ekwall3, J Ungerstedt1, J Kere4, D Greco5, E Hellström-Lindberg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24025691     DOI： 10.1038/leu.2013.265

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors.

Authors:  Ana Aparicio; Brittany North; Lindsey Barske; Xuemei Wang; Valentina Bollati; Daniel Weisenberger; Christine Yoo; Nizar Tannir; Erin Horne; Susan Groshen; Peter Jones; Allen Yang; Jean-Pierre Issa
Journal:  Epigenetics       Date:  2009-04-06       Impact factor: 4.528

2.  5-azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity.

Authors:  N Curik; P Burda; K Vargova; V Pospisil; M Belickova; P Vlckova; F Savvulidi; E Necas; H Hajkova; C Haskovec; J Cermak; M Krivjanska; M Trneny; P Laslo; A Jonasova; T Stopka
Journal:  Leukemia       Date:  2012-02-20       Impact factor: 11.528

3.  Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer.

Authors:  Gary C Hon; R David Hawkins; Otavia L Caballero; Christine Lo; Ryan Lister; Mattia Pelizzola; Armand Valsesia; Zhen Ye; Samantha Kuan; Lee E Edsall; Anamaria Aranha Camargo; Brian J Stevenson; Joseph R Ecker; Vineet Bafna; Robert L Strausberg; Andrew J Simpson; Bing Ren
Journal:  Genome Res       Date:  2011-12-07       Impact factor: 9.043

4.  DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia.

Authors:  Allen S Yang; Ketan D Doshi; Sang-Woon Choi; Joel B Mason; Rajan K Mannari; Vazganush Gharybian; Rene Luna; Asif Rashid; Lanlan Shen; Marcos R H Estecio; Hagop M Kantarjian; Guillermo Garcia-Manero; Jean-Pierre J Issa
Journal:  Cancer Res       Date:  2006-05-15       Impact factor: 12.701

5.  Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy.

Authors:  Michael Grövdal; Mohsen Karimi; Rasheed Khan; Anni Aggerholm; Petar Antunovic; Jan Astermark; Per Bernell; Lena-Maria Engström; Lars Kjeldsen; Olle Linder; Lars Nilsson; Anna Olsson; Mette S Holm; Jon M Tangen; Jonas Wallvik; Gunnar Oberg; Peter Hokland; Sten E Jacobsen; Anna Porwit; Eva Hellström-Lindberg
Journal:  Br J Haematol       Date:  2010-05-20       Impact factor: 6.998

6.  Induction of gene expression by 5-Aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms.

Authors:  K Schmelz; N Sattler; M Wagner; M Lübbert; B Dörken; I Tamm
Journal:  Leukemia       Date:  2005-01       Impact factor: 11.528

7.  Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.

Authors:  Pierre Fenaux; Norbert Gattermann; John F Seymour; Eva Hellström-Lindberg; Ghulam J Mufti; Ulrich Duehrsen; Steven D Gore; Fernando Ramos; Odile Beyne-Rauzy; Alan List; David McKenzie; Jay Backstrom; Charles L Beach
Journal:  Br J Haematol       Date:  2010-02-05       Impact factor: 6.998

8.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

9.  MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation.

Authors:  Maria E Figueroa; Lucy Skrabanek; Yushan Li; Anchalee Jiemjit; Tamer E Fandy; Elisabeth Paietta; Hugo Fernandez; Martin S Tallman; John M Greally; Hetty Carraway; Jonathan D Licht; Steven D Gore; Ari Melnick
Journal:  Blood       Date:  2009-08-03       Impact factor: 22.113

10.  Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines.

Authors:  Matthias Schaefer; Sabine Hagemann; Katharina Hanna; Frank Lyko
Journal:  Cancer Res       Date:  2009-10-06       Impact factor: 12.701
View more
  8 in total

Review 1.  Azacitidine: A Review in Myelodysplastic Syndromes and Acute Myeloid Leukaemia.

Authors:  Lesley J Scott
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

2.  DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes.

Authors:  Brian Reilly; Tiffany N Tanaka; Dinh Diep; Huwate Yeerna; Pablo Tamayo; Kun Zhang; Rafael Bejar
Journal:  Blood Adv       Date:  2019-10-08

3.  Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34+ Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients.

Authors:  Pavla Koralkova; Monika Belickova; David Kundrat; Michaela Dostalova Merkerova; Zdenek Krejcik; Katarina Szikszai; Monika Kaisrlikova; Jitka Vesela; Pavla Vyhlidalova; Jan Stetka; Alzbeta Hlavackova; Jiri Suttnar; Patrik Flodr; Jan Stritesky; Anna Jonasova; Jaroslav Cermak; Vladimir Divoky
Journal:  Cancers (Basel)       Date:  2021-04-30       Impact factor: 6.639

4.  Comprehensive mapping of the effects of azacitidine on DNA methylation, repressive/permissive histone marks and gene expression in primary cells from patients with MDS and MDS-related disease.

Authors:  Magnus Tobiasson; Hani Abdulkadir; Andreas Lennartsson; Shintaro Katayama; Francesco Marabita; Ayla De Paepe; Mohsen Karimi; Kaarel Krjutskov; Elisabet Einarsdottir; Michael Grövdal; Monika Jansson; Asmaa Ben Azenkoud; Lina Corddedu; Sören Lehmann; Karl Ekwall; Juha Kere; Eva Hellström-Lindberg; Johanna Ungerstedt
Journal:  Oncotarget       Date:  2017-04-25

5.  Different methylation signatures at diagnosis in patients with high-risk myelodysplastic syndromes and secondary acute myeloid leukemia predict azacitidine response and longer survival.

Authors:  M Cabezón; R Malinverni; J Bargay; B Xicoy; S Marcé; A Garrido; M Tormo; L Arenillas; R Coll; J Borras; M J Jiménez; M Hoyos; D Valcárcel; L Escoda; F Vall-Llovera; A Garcia; L L Font; E Rámila; M Buschbeck; L Zamora
Journal:  Clin Epigenetics       Date:  2021-01-14       Impact factor: 6.551

6.  Mutations in histone modulators are associated with prolonged survival during azacitidine therapy.

Authors:  Magnus Tobiasson; Donal P McLornan; Mohsen Karimi; Marios Dimitriou; Monika Jansson; Asmaa Ben Azenkoud; Martin Jädersten; Greger Lindberg; Hani Abdulkadir; Austin Kulasekararaj; Johanna Ungerstedt; Andreas Lennartsson; Karl Ekwall; Ghulam J Mufti; Eva Hellström-Lindberg
Journal:  Oncotarget       Date:  2016-04-19

7.  Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome.

Authors:  Ebba Sohlberg; Aline Pfefferle; Sandra Andersson; Bettina C Baumann; Eva Hellström-Lindberg; Karl-Johan Malmberg
Journal:  Oncotarget       Date:  2015-10-27

8.  Chromatin Regulation by HP1γ Contributes to Survival of 5-Azacytidine-Resistant Cells.

Authors:  Satoshi Imanishi; Tomohiro Umezu; Chiaki Kobayashi; Tomohiko Ohta; Kazuma Ohyashiki; Junko H Ohyashiki
Journal:  Front Pharmacol       Date:  2018-10-16       Impact factor: 5.810
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.